Related Experiment Video

Updated: Jun 28, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

The malignant phenotype of breast cancer cells is reduced by COX-2 silencing

Ioannis Stasinopoulos1, Noriko Mori, Zaver M Bhujwalla

  • 1The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Neoplasia (New York, N.Y.)
|October 28, 2008
PubMed

Insights

Silencing cyclooxygenase-2 (COX-2) in metastatic breast cancer cells reduces malignancy. This inhibition affects medium acidification, lactate production, hyaluronan secretion, and endothelial cell network formation, highlighting COX-2

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The cyclooxygenase (COX) pathway, particularly COX-2, is a therapeutic target in various cancers.
  • Previous studies demonstrated that silencing COX-2 in MDA-MB-231 breast cancer cells delays tumor onset and inhibits metastasis.

Purpose of the Study:

  • To elucidate the functional mechanisms by which COX-2 silencing impacts cancer-associated phenotypes.
  • To investigate the role of COX-2 in regulating cellular processes critical for tumor growth and metastasis.

Main Methods:

  • RNA interference was used to silence COX-2 expression in MDA-MB-231 cells.
  • Assays were performed to measure medium acidification, lactate production/export, hyaluronan secretion, and endothelial cell network formation.

Main Results:

  • COX-2-silenced cells exhibited reduced medium acidification and decreased lactate levels.
  • Significant reduction in hyaluronan synthase 2 transcript levels and lower secreted hyaluronan were observed.
  • Inhibition of human umbilical vein endothelial cell network formation was noted in COX-2-silenced cells.

Conclusions:

  • COX-2 plays a crucial functional role in mediating cancer malignancy.
  • Silencing COX-2 impacts key pathways involved in tumor growth, metastasis, and angiogenesis.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...